



HUB ORGANOIDS

A patient in the lab

HUB Tumor Organoid Models Capture the Complexity of Cancer

The Challenge

Advances in our understanding of the molecular basis of cancer have led to explosive growth in the number of oncology drug candidates in development. Despite robust indications of activity in existing preclinical models, such as cell lines and animal models, around 95% of new anticancer drugs fail to reach patients. The high attrition rate in cancer drug development has been attributed to poor translatability of preclinical models. Therefore, it has become clear that more advanced preclinical models – with a direct link to the patient – are needed for drug discovery and development.


HUB Organoid Solution

- adult stem cell-derived HUB Organoids are rapidly and directly generated from the tumor of patients and maintain the tumor heterogeneity *in vitro*.
- HUB Organoids can be used in all conventional and state of the art *in vitro* assays, providing data directly correlating with patient response.

Why HUB Organoids for Oncology Drug Development?

"The only *in vitro* model that enables long-term expansion while maintaining genetic and phenotypic stability."

- captures disease relevance and tumor heterogeneity observed in the patient population.
- allows translation of *in vitro* drug testing data to patient response.
- decreases development time, by integrating early preclinical drug development with patient stratification on patient relevant organoid biobanks.
- high-throughput model for development of combination treatments.
- suitable for genetic and other molecular and biochemical experiments.
- cryopreservation of organoid collections.



Services for Oncology offered by HUB

- tumor organoid and matched healthy organoid biobank collections
- drug screening
- immunohistochemistry, immunofluorescence
- live imaging
- preclinical clinical trials, patient stratification
- mechanism of actions studies
- biomarker development
- companion diagnostic development
- co-culture models: immune cells and tumor organoids
- CAR T – organoid assays
- gene expression analysis (DNA and RNAseq)
- gene editing
- on request:
 - assay development – custom assays upon customer request
 - novel organoid biobanks – establishment of organoid biobanks with specific mutations or tumor types

Hubrecht Organoid Technology

Yalelaan 62
3584 CM Utrecht

The Netherlands
+31 (0)88 1236300

marketing@huborganoids.nl
huborganoids.nl